Skip to main content

Advertisement

SpringerLink
Log in

The use of intermittent human parathyroid hormone as a treatment for osteoporosis

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Parathyroid hormone (PTH), given intermittently, is an anabolic agent. PTH has been demonstrated to increase bone mass and reduce vertebral and nonvertebral fractures, and has been approved for use in the US and Europe. PTH is a genetically engineered 34 amino acid protein with the designation teriparatide (recombinant DNA origin) or recombinant human PTH 1-34. A recombinant DNA preparation with all 84 amino acids of the native PTH molecule is in clinical trials. These PTH preparations are selfadministered daily injections, and it is approved for women and men at high risk for fractures, including patients with prevalent fractures, low bone mass, and multiple risk factors. PTH is likely to be used most frequently in patients who fracture on therapy, but can be used in high-risk treatment-naíve patients. Previous treatment with alendronate appears to impair the anabolic response of PTH preparations. Patients who have Paget’s disease, prior radiation therapy to the skeleton, as well as children and young adults with open epiphyses, are at higher risk for osteosarcoma and should not be given PTH. Patients with hypercalcemia and hyperparathyroidism also should not receive the drug.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Neer R, Arnaud C, Zanchetta JR, et al.: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434–1441. This is a pivotal trial of rhPTH 1-34 that showed vertebral and nonvertebral fracture reduction in postmenopausal women at high risk for fracture.

    Article  PubMed  CAS  Google Scholar 

  2. Dobnig H, Turner RT: The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology 1997, 138:4607–4612.

    Article  PubMed  CAS  Google Scholar 

  3. Reeve J, Meunier P, Parsons JA, et al.: Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. BMJ 1980, 280:1340–1344.

    Article  PubMed  CAS  Google Scholar 

  4. Reeve J, Davies UM, Hesp R, et al.: Human parathyroid peptide treatment of osteoporosis substantially increases spinal trabecular bone. BMJ 1990, 301:314–318.

    PubMed  CAS  Google Scholar 

  5. Reeve J, Bradbeer JN, Arlot M: hPTH (1-34) treatment of osteoporosis with added hormone replacement therapy: biochemical, kinetic, and histological responses. Osteoporos Int 1991, 1:162–170.

    Article  PubMed  CAS  Google Scholar 

  6. Neer M, Slovik DM, Daly N, et al.: Treatment of postmenopausal osteoporosis with daily parathyroid hormone plus calcitriol. Osteoporos Int 1993, 3(suppl):S204-S205.

    Article  Google Scholar 

  7. Lindsay R, Scheele WH, Clancy AD, et al.: Incident vertebral fractures during an 18 month observation period following discontinuation of LY 333334 (recombinant human parathyroid hormone (1-34), rhPTH (1-34)) use in postmenopausal women with osteoporosis. J Bone Miner Res 2001, 16(suppl):S162.

    Google Scholar 

  8. Scheele W: Paper presented the 84th Annual Meeting of the Endocrine Society. San Francisco, CA: June 19–22, 2002.

  9. Orwoll, E, Scheele WH, Clancy AD, et al.: Recombinant human parathyroid hormone (1-34) therapy reduces moderate/ severe vertebral fracture incidence in men with low bone density. J Bone Miner Res 2001, 16(suppl):S162. This is a trial of rhPTH 1-34 in men that demonstrates increases in BMD comparable with women and significant reduction in moderate (26% to 40% height reduction) and severe (>40%) in treated patients.

    Article  Google Scholar 

  10. Lindsay R, Hodsman A, Genant H: A randomized controlled multicenter study of 1-84 hPTH for treatment of postmenopausal osteoporosis. J Bone Miner Res 2000, 15(suppl):S175.

    Article  Google Scholar 

  11. Black DM, Cummings SR, Karpf DB, et al.: Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture intervention trial research group. Lancet 1996, 248:1535–1541.

    Article  Google Scholar 

  12. Ettinger B, Black DM, Mitlak BH, et al.: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999, 282:637–645.

    Article  PubMed  CAS  Google Scholar 

  13. Reginster J, Minne H, Sorensen OH et al.: Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000, 11:83–91.

    Article  PubMed  CAS  Google Scholar 

  14. Harris ST, Watts NB, Genant HK, et al.: Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999, 282:1144–1352.

    Article  Google Scholar 

  15. Lindsay R. Nieves J, Formica C, et al.: Randomized controlled study of effect of parathyroid hormone on vertebral bone mass and fracture incidence among postmenopausal women on estrogen with osteoporosis. Lancet 1997, 350:550–556.

    Article  Google Scholar 

  16. Cosman F, Nieves J, Woelfert L, et al.: Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 2001, 16:925–931. This trial added hPTH 1-34 to estrogen and showed increase in bone mass and fracture reduction with combination therapy.

    Article  PubMed  CAS  Google Scholar 

  17. Ste-Marie LG, Scheele WH, Jasqui S, et al.: Effect of LY 333334 (recombinant human parathyroid hormone (1-34), rhPTH (1-34)) on bone density when given to postmenopausal women receiving hormone replacement therapy (HRT). Paper presented at the 84th Annual Meeting of the Endocrine Society. Denver, CO; June 20–23, 2001.

  18. Ettinger B, San Martin J, Crans GG, et al.: Response of markers of bone turnover and bone density to teriparatide in postmenopausal women previously treated with an antiresorptive drug. J Bone Miner Res 2003, 18(suppl):S15.

    Google Scholar 

  19. Black DM, Greenspan SL, Ensrud KE, et al.: The effects of parathyroid hormone alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003, 349:1207–1215. Alendronate and PTH used together, shows impaired anabolic response to PTH.

    Article  PubMed  CAS  Google Scholar 

  20. Finkelstein JS, Hayes A, Hunzelman JL, et al.: The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003, 349:1216–1226. Study in men that shows the effect of alendronate added to PTH impairs the anabolic response to PTH.

    Article  PubMed  CAS  Google Scholar 

  21. Neer R, Hayes A, Rao A, et al.: Effects of parathyroid hormone, alendronate, or both on bone density in osteoporotic postmenopausal women. J Bone Miner Res 2002, 17(suppl):S135.

    Google Scholar 

  22. Rittmaster RS, Bolognese M, Ettinger MP, et al.: Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 2000, 85:2129–2134. Parathyroid hormone for 1 year followed by alendronate has an additive effect on bone density response with continued increase in bone mass with alendronate therapy.

    Article  PubMed  CAS  Google Scholar 

  23. Hodsman AB, Fraher LJ, Watson PH, et al.: A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 1997, 82:620–628.

    Article  PubMed  CAS  Google Scholar 

  24. McClung M, Miller P, Civitelli R, et al.: Differential effects of teriparatide and alendronate on markers of bone remodeling and areal and volumetric bone density in women with osteoporosis. J Bone Miner Res 2003, 18(suppl):S40.

    Google Scholar 

  25. Body JJ, Gaich GA, Scheele WH, et al.: A randomized controlled clinical trial to compare the efficacy of LY333334 (recombinant human parathyroid hormone (1-34)) and alendronate sodium in postmenopausal women with osteoporosis. J Bone Miner Res 2001, 6(suppl):S179.

    Google Scholar 

  26. Dempster DW, Cosman F, Kurland ES, et al.: Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 2001, 16:1846–1853. This study showed histologic effects of rhPTH 1-34 on trabecular bone, including increase in connectivity and cortical thickness.

    Article  PubMed  CAS  Google Scholar 

  27. Hyldstrup L, Jorgensen JT, Gaich G, et al.: Assessment of effects of LY 333334 (recombinant human parathyroid hormone (1-34)) on cortical bone using digital x-ray radiogrammetry. Bone 2001, 28(suppl):5.

    Google Scholar 

  28. Zanchetta JR, Bogado C, Ferretti JL, et al.: Effects of LY 333334 (recombinant parathyroid hormone (1-34)) on cortical bone strength indices as assessed by peripheral quantitative computed tomography. Bone 2001, 28(suppl):5.

    Google Scholar 

  29. Hodsman AB: Histopomorphic evidence for increased bone turnover without change in cortical thickness or porosity after two years of cyclic hPTH (1-34) therapy and women with severe osteoporosis. Bone 2000, 27:311–318.

    Article  PubMed  CAS  Google Scholar 

  30. Lane NE, Sanchez S, Modin GW, et al.: Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. J Clin Invest 1998, 102:1627–1633.

    Article  PubMed  CAS  Google Scholar 

  31. Lane NE, Sanchez S, Modin GW, et al.: Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J Bone Miner Res 2000, 15:944–951.

    Article  PubMed  CAS  Google Scholar 

  32. Mashiba T., Burr DB, Turner CH, et al.: Effects of a human parathyroid hormone (1-34), LY 333334, on bone mass, remodeling, and mechanical properties of cortical bone during the first remodeling cycle in rabbits. Bone 2001, 28:538–547.

    Article  PubMed  CAS  Google Scholar 

  33. Burr DB, Hirano T, Turner CH, et al.: Intermittently administered human parathyroid hormone (1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of oophorectomized cynomolgus monkeys. JBMR 2001, 16:157–165.

    Article  CAS  Google Scholar 

  34. Garnero P, Hausherr E, Chapuy MC, et al.: Markers of bone resorption predict hip fracture in elderly women: the EPIDOS prospective study. J Bone Miner Res 1996, 11:1531–1538.

    Article  PubMed  CAS  Google Scholar 

  35. Vahle JL, Sato M, Long GG, et al.: Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human data. Toxicol Pathol 2002, 30:312–321.

    Article  PubMed  CAS  Google Scholar 

  36. Forteo teriparatide (rDNA origin) [packaging insert]. Indianapolis, IN: Eli Lilly and Company; 2002.

  37. Lindsay R, Silverman S, Cooper C, et al.: Risk of new vertebral fracture in the year following a fracture. JAMA 2001, 285:320–323.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Osteoporosis and Metabolic Bone Disease, Department of Rheumatology, The Cleveland Clinic Foundation, 9500 Euclid Avenue, 44195, Cleveland, OH, USA

    Chad Deal MD

Authors
  1. Chad Deal MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Deal, C. The use of intermittent human parathyroid hormone as a treatment for osteoporosis. Curr Rheumatol Rep 6, 49–58 (2004). https://doi.org/10.1007/s11926-004-0083-3

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-004-0083-3

Keywords

Search

Navigation